Navigation Links
Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial
Date:1/28/2011

of Vascular Diseases and Surgery. "This clinical trial represents a unique opportunity to evaluate a novel biologic treatment for 'no-option' CLI patients and reinforces Ohio State Medical Center's leadership role in the clinical evaluation of these important technologies to improve the delivery of care for our patients."

Ultimately, Arteriocyte expects this technology to benefit many of the 750,000 individuals suffering from Critical Limb Ischemia in the United States. CLI is caused by a severe blockage of peripheral arteries that significantly impairs blood flow to the extremities, causing chronic tissue degeneration and necrosis. It is estimated that 150,000 individuals lose a limb due to this disease each year(1).

Arteriocyte's Chief Executive Officer, Don Brown shared, "We're thrilled to have the green light to initiate this next important step in the clinical development program for the Magellan MAR01™ technology. It represents yet another achievement in our public-private partnership with Ohio's Third Frontier Program, and their support of our development of Magellan based cellular therapies for the treatment of cardiovascular and critical limb ischemia patients."

About Arteriocyte

Arteriocyte, a leading clinical stage biotechnology company, is dedicated in developing novel stem cell products and medical devices for unmet research and clinical needs. Arteriocyte leverages its expertise in stem cell and tissue engineering in order to develop a broad portfolio of cell based therapeutics to improve patient outcomes. In October of 2007, Arteriocyte partnered with DW Healthcare Partners and Comerica to create Arteriocyte Medical Systems Inc., in order to commercialize and distribute novel medical devices and point of care surgical solutions to address serious unmet medical needs in cardiac, orthopedic and vascular surgeries. Today, Arteriocyte Medical Systems manufactures and distributes the Magellan® Autologous Plat
'/>"/>

SOURCE Arteriocyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
2. 3SBio Inc. Receives SFDA Approval for TPIAO Label Extension for the Treatment of ITP
3. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
4. Regenicin Receives Positive Feedback at OneMedForum Conference
5. Neogens Rapid Test for Salmonella enteritidis Receives FDA Approval
6. Regenicin COO Receives Citizenship Award from VFW Post 1 in Colorado
7. Foundation Venture Capital Group Company Receives $8.2 Million DoD Contract
8. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
9. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
10. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... DIEGO , April 24, 2015  Pfenex Inc. ... the development of biosimilar therapeutics including high value and ... its follow-on public offering of 6,000,000 shares of its ... $15.50 per share. Of the shares being offered, 2,610,000 ... shares are being offered by existing stockholders. Pfenex will ...
(Date:4/24/2015)... Seoul Semiconductor announced the expansion of ... the lighting market. In recent months, there ... in emerging markets such as Russia, South America, ... applications such as streetlight and area lighting, tunnel ... launched in 2005 the Acrich technology from Seoul ...
(Date:4/23/2015)... , April 23, 2015 /CNW/ - A new and ... award from North America,s ... Comparison won Silver in the "Sustainability, service" category ... The Brandcheck "Competitor Comparison" is a service that ... American and Global peers. This benchmarking process shows ...
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology and medical device industries, with operations ... the United States , today announced that it ... 2015 after the New York Stock Exchange closes on ... May 14, 2015 Shanghai time). The earnings release will ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... Terumo Americas Holding, Inc., a U.S. subsidiary of Japan,s ... manufacturers with $3.4 billion in sales and operations in ... entered into a Stock Purchase Agreement to acquire all ... company working to commercialize the world,s first point-of-care technology ...
... make it possible to improve photoelectrochemical cells. In the ... into energy, these cells use sunlight to drive chemical ... involves using a light-sensitive semi-conducting material such as cuprous ... reaction. Although it is not expensive, the oxide is ...
... 2011 Biocept, Inc., a privately-held laboratory testing ... of circulating tumor cells (CTCs) in cancer patients, ... the identification of different CTC phenotypes using its ... paper, appearing in the Journal of Oncology ...
Cached Biology Technology:Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy 2Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy 3Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy 4Harnessing the energy of the Sun: New technique improves artificial photosynthesis 2Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients 2Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients 3
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... adequate amount of the mineral phosphate can turn a common ... in the April 14, 2009, issue of the Proceedings ... lead to new drugs that would disarm the increasingly antibiotic-resistant ... aeruginosa is one of the most serious hospital-acquired pathogens. ...
... identified a gene that controls the rapid production and ... cell types -- a discovery that could eventually open ... other blood cancers, in which blood cells proliferate out ... of this gene, the scientists uncovered evidence that could ...
... to President Obama, more than 200 organizations, representing the ... President for his outstanding leadership in advancing scientific research, ... below. Dear Mr. President: On ... communities, we wish to commend you and your Administration ...
Cached Biology News:Research could lead to new non-antibiotic drugs to counter hospital infections 2Research could lead to new non-antibiotic drugs to counter hospital infections 3Scientists identify key gene that protects against leukemia 2Scientists identify key gene that protects against leukemia 3Business, scientific, higher education groups laud President Obama's commitment to science 2
... flexible and easy to use ... control all members of the ... features a clear and easy-to-follow ... setup, user-friendly and highly sophisticated ...
Strip Removal Tool 25/Box...
The bench-top stand comfortably holds up to 6 Finnpipette Digital single- and multichannel pipettes. The crossbars are made of a grippy material to keep the pipettes firmly in place. Individual shelf...
... Analysis Note: Protein determined by Biuret Physical ... mM Tris-HCl, pH 7.6, 1 mM MgCl ... Preparation Unit Definition: One unit will ... minute at pH 9.8 at 37 C. ...
Biology Products: